10-Q: Treace Medical Q3 Revenue Up 11.4%, Net Loss Widens Amid Legal Costs

Treace Medical Concepts reports an 11.4% revenue increase in Q3 2025, driven by new product sales and initial stocking orders, but faces increased net losses due to rising legal and operating expenses.

Summary

• Revenue for Q3 2025 increased by 11.4% to $50.2 million, and by 6.8% to $150.2 million for the nine months ended September 30, 2025, compared to the same periods in 2024.
• The increase in revenue was primarily due to a higher volume of bunion procedure kits sold, including $6.0 million in Q3 and $11.0 million for the nine months from initial stocking orders by new distributors.
• Net loss for Q3 2025 widened to $16.3 million from $15.4 million in Q3 2024, while the net loss for the nine months improved to $49.6 million from $55.2 million in the prior year.
• Gross profit margin decreased to 79.1% in Q3 2025 from 80.1% in Q3 2024, mainly due to lower-margin sales to stocking distributors and increased inventory provisions.
• General and administrative expenses rose significantly by 20.4% in Q3 and 14.5% for the nine months, primarily driven by a $2.9 million increase in legal fees related to ongoing litigation.
• Cash and cash equivalents decreased to $7.7 million as of September 30, 2025, from $11.4 million at December 31, 2024, with marketable securities also declining.
• Net cash used in operating activities significantly improved to $7.9 million for the nine months ended September 30, 2025, compared to $33.0 million in the prior year.

Sentiment

Score: 4

Explanation: While revenue growth continues, the widening net loss in Q3, declining gross margins, and substantial increase in legal expenses are concerning. The reliance on initial stocking orders for a significant portion of Q3 revenue growth is not sustainable. The company faces increasing competition and multiple ongoing legal battles, which introduce significant financial and operational uncertainty. Although cash burn from operations improved for the nine-month period, overall cash and marketable securities declined, and the company acknowledges potential future capital raises.

Positives

• Revenue increased by 11.4% in Q3 2025 to $50.2 million and by 6.8% for the nine months to $150.2 million, indicating continued sales growth.
• Net cash used in operating activities significantly improved to $7.9 million for the nine months ended September 30, 2025, from $33.0 million in the prior year, reflecting better cash management.
• Sales and marketing expenses decreased by 6.5% for the nine months ended September 30, 2025, due to optimization of the direct employee sales force and reduced direct-to-consumer advertising.
• The company continues to innovate, with several new products launched in late 2024 and early 2025, including minimally-invasive osteotomy systems and specialized implants.
• The company successfully extended its interest-only period on the MidCap term loan to 60 months due to meeting required revenue levels.

Negatives

• Net loss increased by 6.0% in Q3 2025 to $16.3 million, primarily due to higher operating expenses.
• Gross profit margin decreased to 79.1% in Q3 2025 and 79.5% for the nine months, mainly due to lower-margin sales to stocking distributors and increased inventory provisions.
• General and administrative expenses increased significantly by 20.4% in Q3 and 14.5% for the nine months, largely driven by a $2.9 million increase in legal fees related to ongoing litigation.
• Sales of the flagship Lapiplasty System are experiencing declines due to evolving surgeon preferences for minimally invasive osteotomy procedures, increased competition, and lower patient demand for elective bunion surgery.
• Cash and cash equivalents decreased to $7.7 million as of September 30, 2025, from $11.4 million at December 31, 2024, and marketable securities also declined, reducing overall liquidity.
• Interest income decreased by 40.6% in Q3 and 43.4% for the nine months due to lower balances invested in marketable securities.
• Initial stocking orders from distributors, which contributed significantly to revenue growth, are not expected to recur at the same level in future quarters.

Risks

• Intense competition from new Lapidus products and accelerating adoption of minimally invasive osteotomy solutions may negatively impact growth rates, market share, and results of operations.
• Lower average selling prices of new bunion systems (Nanoplasty, Percuplasty) compared to the Lapiplasty System could adversely affect revenues if they do not sufficiently offset declines in Lapiplasty sales.
• Macroeconomic uncertainties, including inflation, recession fears, reduced consumer confidence, and higher insurance deductibles, may continue to negatively impact consumer demand for elective surgeries.
• Protracted government shutdowns and evolving U.S. tariff policies could increase inventory costs and reduce gross margins.
• The company is involved in multiple legal proceedings, including patent infringement lawsuits (against Stryker and Zimmer Biomet/Paragon 28, and being sued by Stryker/Howmedica Osteonics Corp. and Paragon 28/Disior Oy) and a federal securities class action, which could result in significant monetary damages, costs, and attorneys' fees.
• The outcome of legal proceedings is uncertain, and the potential impact on the business or financial statements cannot be reasonably estimated at this time.
• Reliance on single-source suppliers for some materials and components poses a supply chain risk.
• Seasonality in sales volumes, with higher sales in Q4 and lower sales in Q1, Q2, and Q3, can lead to fluctuations in revenue.
• The ability to obtain and maintain intellectual property protection and successfully defend against infringement is crucial for business success.
• The company expects to continue operating at a loss in the near term and may need to raise additional debt or equity financing, which could dilute stockholders or involve restrictive covenants.
• The economic success and viability of hospitals, ambulatory surgery centers, surgeons, and stocking distributors that buy products impact sales.
• Softening demand could lead to slower usage of products already purchased by stocking distributors, impacting future product revenues.

Future Outlook

The company expects revenue to increase in absolute dollars in the foreseeable future due to expanded product offerings, new accounts, and trained physician base, though growth rates may fluctuate due to seasonality, macroeconomic conditions, and competition. It anticipates continued operating losses in the near term, with funding primarily from existing cash, marketable securities, available debt, and expected revenues. The company plans further innovations in 2026, including the Lapiplasty Lightning platform, new compression screws, and additional SpeedPlate implants.

Management Comments

• "We believe that our existing cash and cash equivalents, marketable securities, available debt borrowings and expected revenues will be sufficient to meet our capital requirements and fund our operations for at least twelve months from the date of issuance of these condensed financial statements."
• "We intend to extend the interest-only period [of the MidCap term loan] to 60 months."
• "We expect our revenue to increase in absolute dollars in the foreseeable future as we expand our product offerings, new accounts and trained physician base, and as existing physician customers that use our products perform more procedures using our products, although our rate of revenue growth may fluctuate from quarter to quarter due to a variety of factors, including seasonality, the macroeconomic environment and competition."
• "In the near term, we expect we will continue to operate at a loss, and we anticipate we will finance our operations principally through the use of our cash and cash equivalents, marketable securities, and expected revenues."
• "We dispute the allegations in the complaint [shareholder class action] and intend to defend against this complaint vigorously."
• "We dispute the allegations in the complaint [Stryker/Howmedica patent infringement] and moved to dismiss all of the claims in the suit."

Industry Context

The medical technology industry for bunion and midfoot deformities is experiencing increased competition, particularly from minimally invasive osteotomy solutions. Treace Medical Concepts is responding by expanding its product portfolio beyond its flagship Lapiplasty System to include new minimally invasive options and complementary products. The demand for elective surgeries, where these products are used, remains sensitive to macroeconomic conditions, including inflation, consumer confidence, and insurance deductibles. The company's strategy to become a comprehensive bunion solutions provider aligns with a broader trend of offering diverse solutions to capture market share in a competitive environment.

Legal Proceedings

• Shareholder Class Action (McCluney v. Treace Medical Concepts, Inc. et al.): Filed April 11, 2025, in the U.S. District Court for the Middle District of Florida. Alleges violations of federal securities laws by making false or misleading statements and failing to disclose material adverse facts about competition and the need for new products. Plaintiffs seek unspecified monetary damages, costs, and attorneys' fees. The company filed a motion to dismiss on September 5, 2025. Outcome is uncertain.
• Patent Infringement Lawsuit against Stryker Corporation and Wright Medical Technology, Inc.: Filed October 14, 2024, in the U.S. District Court for the District of New Jersey. Alleges infringement of 9 patents related to Lapiplasty 3D Bunion Correction technologies and unfair competition. Seeks injunctive relief and damages. Stryker's motion to dismiss unfair competition claims was granted without prejudice on October 2, 2025. The company filed a first amended complaint on October 24, 2025.
• Patent Infringement Lawsuit by Stryker European Operations Holdings LLC and Howmedica Osteonics Corp.: Filed May 23, 2025. Alleges patent infringement by Treace Medical Concepts' hammertoe product. Plaintiffs seek findings of infringement, equitable relief, unspecified monetary damages, enhanced damages for willful infringement, interest, costs, and attorneys' fees. Treace Medical Concepts moved to dismiss all claims on August 4, 2025. Outcome is uncertain.
• Patent Infringement Lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc.: Filed May 12, 2025, in the U.S. District Court for the District of Delaware. Alleges infringement of 4 patents (amended to 5 on August 5, 2025) related to Lapiplasty 3D Bunion Correction technologies. Seeks injunctive relief and damages.
• Trade Secret Misappropriation Lawsuit by Paragon 28, Inc. and Disior Oy: Filed August 29, 2025, in the U.S. District Court for the District of Delaware. Alleges RPM-3D (acquired by Treace Medical Concepts) improperly acquired, used, and disclosed confidential and trade secret technology from Disior's software to develop software acquired by Treace Medical Concepts. Seeks injunctive relief and damages. Deadline to respond is December 10, 2025.

Related Party Transactions

• Royalty agreements with surgeon consultants for product development, with royalty expense of $1.6 million for Q3 2025 and $4.7 million for 9M 2025. These agreements prohibit royalty payments on products sold to entities/individuals affiliated with the surgeon consultants.

Stakeholder Impact

• Shareholders: Potential dilution from future equity raises, uncertainty from ongoing litigation, and impact on stock price from financial performance and legal outcomes.
• Employees: Restructuring charge in sales and marketing includes severance and post-employment benefits, indicating some workforce adjustments. Increased headcount in R&D.
• Customers (Hospitals, ASCs, Stocking Distributors): Continued product innovation aims to provide better solutions. Stocking distributors are a new sales channel, but initial stocking orders are not expected to recur at the same level.
• Suppliers: Potential for increased inventory costs due to tariffs. Reliance on single-source suppliers for some components.
• Creditors: The company has significant long-term debt ($53.5 million) and has secured its loans with substantially all assets. Legal cost financing adds to current debt.

Next Steps

• Continue to expand product offerings and trained physician base.
• Educate hospitals and facility administrators on the benefits of procedures and systems.
• Develop additional clinical data on new products.
• Expand commercial availability of new products and release other new solutions during 2025, including the Percuplasty MIS Power System and biologics.
• Begin offering additional innovations in 2026, including the Lapiplasty Lightning platform, new compression screws, and additional procedure-specific SpeedPlate implants and sterile instruments.
• Defend vigorously against the shareholder class action complaint and other patent infringement lawsuits.
• Respond to the Paragon 28/Disior Oy complaint by December 10, 2025.
• Monitor further developments in legal proceedings that could affect accrued liabilities.
• Evaluate the impact of new accounting standards (ASU 2023-09, ASU 2024-03, ASU 2025-06) on financial statements and disclosures.

Key Dates

Recommendation

While Treace Medical Concepts demonstrates continued revenue growth and an improved cash burn from operations over the nine-month period, the Q3 results show a widening net loss and declining gross margins, partly due to lower-margin distributor sales and increased legal expenses. The company faces significant competitive pressures on its flagship product and is embroiled in multiple complex and costly legal battles, including patent infringement and a securities class action, which introduce substantial uncertainty and financial risk. The reliance on initial stocking orders for recent revenue growth is not sustainable. Given the mixed financial performance, the ongoing legal overhang, and the need for potential future capital raises, a 'hold' recommendation is appropriate. Investors should monitor the outcomes of the legal proceedings, the sustainability of revenue growth from new products, and the company's ability to manage its operating expenses and cash flow effectively before considering further investment.

Keywords

Bunion Correction, Lapiplasty, Medical Technology, Orthopedic Devices, Foot and Ankle Surgery, Minimally Invasive Surgery, SEC Filing, Financial Results, Q3 2025, TMCI, Patent Litigation, Healthcare, Elective Surgery